US › Healthcare

Compugen (CGEN)

US · Healthcare · Biotechnology

$1.96+2.08%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$2.6M

Revenue YoY

+107.0%

Net profit

$-7.0M

EPS

$-0.07

EPS estimate

$-0.07

Net margin

-269.3%

EPS came in at -0.07 against a street estimate of -0.07 — a beat of 0.0%.

Key statistics

Market cap

$181.9M

P/E

5.1

Forward P/E

12.4

P/B

2.17

Book value

$0.94

EPS (TTM)

$0.38

52-week high

$3.23

52-week low

$1.43

50-day MA

$2.28

200-day MA

$2.29

Beta

2.82

Analyst view

Analysts rate Compugen a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $4.60.

Shareholding

Insiders

0.39%

Institutions

15.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Compugen — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.